Logo image of TOI

ONCOLOGY INSTITUTE INC/THE (TOI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TOI - US68236X1000 - Common Stock

3.35 USD
-0.01 (-0.3%)
Last: 1/16/2026, 8:00:01 PM
3.41 USD
+0.06 (+1.79%)
After Hours: 1/16/2026, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, TOI scores 2 out of 10 in our fundamental rating. TOI was compared to 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of TOI have multiple concerns. TOI shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • TOI had negative earnings in the past year.
  • TOI had a negative operating cash flow in the past year.
  • TOI had negative earnings in 4 of the past 5 years.
  • TOI had negative operating cash flow in 4 of the past 5 years.
TOI Yearly Net Income VS EBIT VS OCF VS FCFTOI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • TOI has a worse Return On Assets (-33.41%) than 84.31% of its industry peers.
Industry RankSector Rank
ROA -33.41%
ROE N/A
ROIC N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
TOI Yearly ROA, ROE, ROICTOI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 14.82%, TOI is doing worse than 63.73% of the companies in the same industry.
  • TOI's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TOI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
TOI Yearly Profit, Operating, Gross MarginsTOI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

  • TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TOI has been increased compared to 1 year ago.
  • The number of shares outstanding for TOI has been increased compared to 5 years ago.
  • Compared to 1 year ago, TOI has a worse debt to assets ratio.
TOI Yearly Shares OutstandingTOI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TOI Yearly Total Debt VS Total AssetsTOI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • TOI has an Altman-Z score of 1.18. This is a bad value and indicates that TOI is not financially healthy and even has some risk of bankruptcy.
  • TOI's Altman-Z score of 1.18 is on the low side compared to the rest of the industry. TOI is outperformed by 68.63% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.18
ROIC/WACCN/A
WACC8.65%
TOI Yearly LT Debt VS Equity VS FCFTOI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • TOI has a Current Ratio of 1.68. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.68, TOI is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • TOI has a Quick Ratio of 1.39. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
  • TOI has a Quick ratio (1.39) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.68
Quick Ratio 1.39
TOI Yearly Current Assets VS Current LiabilitesTOI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 16.56% over the past year.
  • Looking at the last year, TOI shows a very strong growth in Revenue. The Revenue has grown by 21.67%.
  • Measured over the past years, TOI shows a very strong growth in Revenue. The Revenue has been growing by 20.41% on average per year.
EPS 1Y (TTM)16.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)21.67%
Revenue growth 3Y24.68%
Revenue growth 5Y20.41%
Sales Q2Q%36.7%

3.2 Future

  • TOI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.78% yearly.
  • TOI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.17% yearly.
EPS Next Y-36.9%
EPS Next 2Y12.33%
EPS Next 3Y20.78%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y22.12%
Revenue Next 3Y21.17%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
TOI Yearly Revenue VS EstimatesTOI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
TOI Yearly EPS VS EstimatesTOI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TOI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TOI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOI Price Earnings VS Forward Price EarningsTOI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOI Per share dataTOI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • TOI's earnings are expected to grow with 20.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.33%
EPS Next 3Y20.78%

More info and screens

0

5. Dividend

5.1 Amount

  • TOI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ONCOLOGY INSTITUTE INC/THE

NASDAQ:TOI (1/16/2026, 8:00:01 PM)

After market: 3.41 +0.06 (+1.79%)

3.35

-0.01 (-0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners40.02%
Inst Owner Change-0.05%
Ins Owners3.63%
Ins Owner Change-58.87%
Market Cap329.57M
Revenue(TTM)461.04M
Net Income(TTM)-54.66M
Analysts82.5
Price Target6.63 (97.91%)
Short Float %8.32%
Short Ratio3.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.28%
Min EPS beat(2)-22.31%
Max EPS beat(2)-14.24%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.88%
Min Revenue beat(2)3.5%
Max Revenue beat(2)10.26%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-3.29%
EPS NY rev (3m)-5.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS4.69
BVpS-0.12
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.82%
FCFM N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
F-Score4
Asset Turnover2.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.49%
Cap/Sales 0.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.68
Quick Ratio 1.39
Altman-Z 1.18
F-Score4
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)87.81%
Cap/Depr(5y)78.43%
Cap/Sales(3y)1.52%
Cap/Sales(5y)1.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y-36.9%
EPS Next 2Y12.33%
EPS Next 3Y20.78%
EPS Next 5YN/A
Revenue 1Y (TTM)21.67%
Revenue growth 3Y24.68%
Revenue growth 5Y20.41%
Sales Q2Q%36.7%
Revenue Next Year20.72%
Revenue Next 2Y22.12%
Revenue Next 3Y21.17%
Revenue Next 5YN/A
EBIT growth 1Y35.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.83%
EBIT Next 3Y44.04%
EBIT Next 5YN/A
FCF growth 1Y47.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.09%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOLOGY INSTITUTE INC/THE / TOI FAQ

Can you provide the ChartMill fundamental rating for ONCOLOGY INSTITUTE INC/THE?

ChartMill assigns a fundamental rating of 2 / 10 to TOI.


Can you provide the valuation status for ONCOLOGY INSTITUTE INC/THE?

ChartMill assigns a valuation rating of 1 / 10 to ONCOLOGY INSTITUTE INC/THE (TOI). This can be considered as Overvalued.


How profitable is ONCOLOGY INSTITUTE INC/THE (TOI) stock?

ONCOLOGY INSTITUTE INC/THE (TOI) has a profitability rating of 0 / 10.


Can you provide the financial health for TOI stock?

The financial health rating of ONCOLOGY INSTITUTE INC/THE (TOI) is 2 / 10.


Can you provide the expected EPS growth for TOI stock?

The Earnings per Share (EPS) of ONCOLOGY INSTITUTE INC/THE (TOI) is expected to decline by -36.9% in the next year.